tislelizumab,sorafenib
beigene,bayer,Novartis
[]
#tislelizumab as frontline therapy for unresectable hepatocellular carcinoma had superior health-related quality of life outcomes vs sorafenib. #gi23 #gicsm #hcc | 
Oncology news and insights from leading researchers and cancer centers.